Talent Testing Service (TTS), announce the release of its March 2026 update featuring the latest positivity rates of Sexually Transmitted Diseases (STDs)...
Talent Testing Service (TTS), announce the release of its March 2026 update featuring the latest positivity rates of Sexually Transmitted Diseases (STDs).
Chlamydia Urine - Positivity Index

Overall, the three Chlamydia Urine rates show a similar behavior through time including the steady downward trend from the November 2022 peak. In March 2026 the three rates increased, the Total rate to 1.1% from 0.7%, the Male rate to 1.0% from 0.9%, and the Female rate to 1.1% from 0.4%. Seeing that historic levels have been around 2.0%, the current rates being below 2.0% can be considered to be within expectations.
GC (Gonorrhea) Urine - Positivity Index

In March 2026 the three Gonorrhea Urine rates moved in tandem again, turning to 0.3% from 0.2%. In this month the three rates continue along a range between 0.0% and 1.0%.
Trichomonas Vaginalis Urine- Positivity Index

In March 2026 all the Trichomonas Vaginalis Urine rates increased, the Total rate to 0.6% from 0.4%, the Female rate to 0.9% from 0.8%, and the Male rate to 0.3% from 0.1%. The current rate levels are still within the general range of 0.0% to 1.5%.
Mycoplasma Genitalium Urine - Positivity Index

In March 2026, all the Mycoplasma G. Urine rates decreased, changing their direction for the first time in four months, the Female rate to 3.6% from 4.9%, the Total rate to 2.9% from 4.3%, and the Male rate to 2.2% from 3.8%.
Chlamydia & GC (Gonorrhea) Throat and Rectal Swabs - Positivity Index

Based on market activity, the positivity rates for the four tests below have December 2022 as a relevant, starting point where all levels display their peak and then start overall downward trends. In March 2026, the three Chlamydia Rectal rates decreased, the Total rate to 1.0% from 1.7%, the Female rate to 1.3% from 2.1%, and the Male rate to 0.6% from 1.2%. The three Chlamydia Throat rates increased, the Total rate to 0.4% from 0.2%, the Male rate to 0.3% from 0.1%, and the Female rate to 0.4% from 0.3%. Although within an overall smaller range of 0.0% to 3.5%, when compared to the other swab rates, the volatility of the Gonorrhea Rectal lines is visible since April 2023, showing decrease in March 2026 for the three rates, the Female rate to 0.4% from 0.6%, the Male rate to 0.8% from 1.3%, and the Total rate to 0.6% from 1.0%. The Gonorrhea Throat rates have two of them increasing, the Total rate to 0.9% from 0.8% and the Male rate to 1%.
Chlamydia Urine - Positivity Index

Overall, the three Chlamydia Urine rates show a similar behavior through time including the steady downward trend from the November 2022 peak. In March 2026 the three rates increased, the Total rate to 1.1% from 0.7%, the Male rate to 1.0% from 0.9%, and the Female rate to 1.1% from 0.4%. Seeing that historic levels have been around 2.0%, the current rates being below 2.0% can be considered to be within expectations.
GC (Gonorrhea) Urine - Positivity Index

In March 2026 the three Gonorrhea Urine rates moved in tandem again, turning to 0.3% from 0.2%. In this month the three rates continue along a range between 0.0% and 1.0%.
Trichomonas Vaginalis Urine- Positivity Index

In March 2026 all the Trichomonas Vaginalis Urine rates increased, the Total rate to 0.6% from 0.4%, the Female rate to 0.9% from 0.8%, and the Male rate to 0.3% from 0.1%. The current rate levels are still within the general range of 0.0% to 1.5%.
Mycoplasma Genitalium Urine - Positivity Index

In March 2026, all the Mycoplasma G. Urine rates decreased, changing their direction for the first time in four months, the Female rate to 3.6% from 4.9%, the Total rate to 2.9% from 4.3%, and the Male rate to 2.2% from 3.8%.
Chlamydia & GC (Gonorrhea) Throat and Rectal Swabs - Positivity Index

Based on market activity, the positivity rates for the four tests below have December 2022 as a relevant, starting point where all levels display their peak and then start overall downward trends. In March 2026, the three Chlamydia Rectal rates decreased, the Total rate to 1.0% from 1.7%, the Female rate to 1.3% from 2.1%, and the Male rate to 0.6% from 1.2%. The three Chlamydia Throat rates increased, the Total rate to 0.4% from 0.2%, the Male rate to 0.3% from 0.1%, and the Female rate to 0.4% from 0.3%. Although within an overall smaller range of 0.0% to 3.5%, when compared to the other swab rates, the volatility of the Gonorrhea Rectal lines is visible since April 2023, showing decrease in March 2026 for the three rates, the Female rate to 0.4% from 0.6%, the Male rate to 0.8% from 1.3%, and the Total rate to 0.6% from 1.0%. The Gonorrhea Throat rates have two of them increasing, the Total rate to 0.9% from 0.8% and the Male rate to 1%.
